1. Academic Validation
  2. A novel human dendritic cell-derived C1r-like serine protease analog inhibits complement-mediated cytotoxicity

A novel human dendritic cell-derived C1r-like serine protease analog inhibits complement-mediated cytotoxicity

  • Biochem Biophys Res Commun. 2004 Aug 20;321(2):329-36. doi: 10.1016/j.bbrc.2004.06.127.
Naisong Lin 1 Shuxun Liu Nan Li Pingping Wu Huazhang An Yizhi Yu Tao Wan Xuetao Cao
Affiliations

Affiliation

  • 1 Institute of Immunology, Zhejiang University, 353 Yan'an Road, Hangzhou 310031, PR China.
Abstract

Trypsin-like serine proteases are involved in diverse biological processes such as complement activation, tissue remodeling, cellular migration, tumor invasion, and metastasis. Here we report a novel human C1r-like serine protease analog, CLSPa, derived from dendritic cells (DC). The 487-residue CLSPa protein contains a CUB domain and a serine protease domain, possessing characteristic catalytic triad but lacking typical activation/cleavage sequence. It shares great homology with complement C1r/C1s and mannose-associated serine proteases. CLSPa mRNA is widely expressed, especially abundant in placenta, liver, kidney, pancreas, and myeloid cells, which are a major resources of serine proteases. Upon stimulation by agonistic anti-CD40 Ab, TNF-alpha, or LPS, CLSPa mRNA expression was significantly up-regulated in monocytic cells and monocyte-derived immature DC. When overexpressed in 293T cells, CLSPa protein was synthesized into the culture supernatants as a secretory protein, which had an inhibitory effect on complement-mediated cytotoxicity to antibody-sensitized erythrocytes. However, CLSPa itself possesses little protease activity, but it plays an inhibitory role in Other active protease catalytic processes. The identification of human CLSPa as a novel Clr-like protein might facilitate future investigation of the regulatory mechanism of CLSPa in complement pathways during inflammation.

Figures